TO Approved for public release, distribution unlimited

Similar documents
SUMMARY OF PRODUCT CHARACTERISTICS

Federal Expert Select Agent Panel (FESAP) Deliberations

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

Revaccination with a reduced dose of Brucella abortus strain 19 vaccine of breeding cows in the Pampas region of Argentina

Brucellosis situation in Mongolia and Result of Bovine Brucellosis Proficiency Test

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

7. Flock book and computer registration and selection

Cercetări bacteriologice, epidemiologice şi serologice în bruceloza ovină ABSTRACT

and other serological tests in experimentally infected cattle

Abortions and causes of death in newborn sheep and goats

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

Implementation of Bovine and Small Ruminant s Brucellosis Eradication Programmes in Portugal PAFF Standing Committee Brussels, 8 June 2017

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Surveillance of animal brucellosis

DOWNLOAD OR READ : VIRAL DISEASES OF CATTLE 2ND EDITION PDF EBOOK EPUB MOBI

Level II Agricultural Business Operations - Assessment Booklet

Master Shepherd s Course Participant application form

Accidental Exposure to Cattle Brucellosis Vaccines in Wyoming, Montana, and Idaho Veterinarians

Presentation Outline. Commercial RVF vaccines. RVF Clone 13 performance in the field. Candidate RVF vaccines in the pipeline

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Brucellosis and Yellowstone Bison

Early lambing with: Improved fertility Improved fecundity Improved prolificacy Compact lambing period Normal return to season Normal sexual cycle

reviewed. One is associated with recovery from natural or experimental infection

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

EUROPEAN REFERENCE LABORATORY (EU-RL) FOR BOVINE TUBERCULOSIS WORK-PROGRAMME PROPOSAL Version 2 VISAVET. Universidad Complutense de Madrid

INFECTIOUS ABORTION INVESTIGATIONS

B. PACKAGE LEAFLET 1

UNCLASSIFIED AD ARMED SERVICES TECHNICAL INFORMATION AGENCY ARLINGTON HALL STATION ARLINGTON 12, VIRGINIA UNCLASSIFIED

Country Report Malaysia. Norazura A. Hamid Department of Veterinary Services, Malaysia

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Assuring Quality: A guide for youth livestock producers Activity for 2008

Improving consumer protection against zoonotic diseases Phase II Project No: EuropeAid/133990/C/SER/AL

Wildlife/Livestock Disease Investigations Team (WiLDIT) Brucellosis Research Update

DISCOVERY OF A. CASE OF ANTHRAX THROUGH BACTERIOLOGICAL INSPECTION OF MEAT. By H. Voelker. - East Germany - Distributed*", jbyt

Table1. Target lamb pre-weaning daily live weight gain from grazed pasture

2019 NATIONAL WESTERN STOCK SHOW (NWSS) LIVESTOCK HEALTH REQUIREMENTS

DISEASE SITUATION AND ACTIVITIES

BRUCELLOSIS BRUCELLOSIS. CPMP/4048/01, rev. 3 1/7 EMEA 2002

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

2018 NATIONAL WESTERN STOCK SHOW (NWSS) HEALTH REQUIREMENTS

Summary of Product Characteristics

Reproductive Vaccination- Deciphering the MLV impact on fertility

Immunological Response of Awassi Sheep to Conjunctival Vaccination against Brucellosis Disease in Mount Lebanon

Brucellosis of Cattle' (Bang's Disease)

Medical Bacteriology- Lecture 14. Gram negative coccobacilli. Zoonosis. Brucella. Yersinia. Francesiella

The Contagious Diseases (Animals) Act

TITLE: Anti-Inflammatory Cytokine Il-10 and Mammary Gland Development. CONTRACTING ORGANIZATION: University of Buffalo Buffalo, New York

TAJIKISTAN. Main breeding systems of sheep in Tajikistan

Brucellosis in Bangladesh. Dr. Md. Habibur Rahman SSO, LRI Department of Livestock Services (DLS) Bangladesh March 2014

Example 1: Quality Assurance Individual

EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL. Unit G5 - Veterinary Programmes

The use of different Brucella vaccines for protection against Brucella melitensis infection in cattle.

Gye and Cramer (1919) found that the ionizable salts of calcium injected together with the washed spores of Cl. tetani or of certain

The Salmonella. Dr. Hala Al Daghisatni

Diseases of Small Ruminants and OIE Standards, Emphasis on PPR. Dr Ahmed M. Hassan Veterinary Expert 7 9 April, 2009 Beirut (Lebanon)

Terms of Reference (TOR) for a Short term assignment. Policy and Legal Advice Centre (PLAC), Serbia

Vaccines for Cats. 2. Feline viral rhinotracheitis, FVR caused by FVR virus, also known as herpes virus type 1, FHV-1

Emerging diseases but don t forget the old ones! Lynn Batty

Summary of Product Characteristics

14th Conference of the OIE Regional Commission for Africa. Arusha (Tanzania), January 2001

Curriculum Vitae. : AlBaha University, faculty of Science.

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MANY PEOPLE feel that

The Economics of Antibiotic Use in U.S. Livestock Agriculture

SUMMARY OF PRODUCT CHARACTERISTICS

THE INFLUENCE OF STREPTOCOCCUS ALLER- GEN AND STREPTOLYSIN 0 ON THE FORMA- TION OF ANTITETANUS IMMUNITY DISTRIBUTED BY:

Field solution for the Artificial Insemination of Ethiopian Sheep Breeds

DEPARTMENT OF THE ARMY South Plains District Veterinary Command North Texas Branch Fort Hood, TX FH-VTF FEB 2009

WOOL DESK REPORT MAY 2007

Outlines. Introduction Prevalence Resistance Clinical presentation Diagnosis Management Prevention Case presentation Achievements

Basics of Sheep Health Care

Coccidiosis in Lambs. Dr Fiona Lovatt. Flock Health Ltd. RCVS Recognised Specialist in Sheep Health & Production

Guideline for Prevention of Brucellosis in Meat Packing Plant Workers

Classificatie: intern

Syllabus 2018/2019. Description of the course MICROBIOLOGY (1) Year of studies II Semester Winter X Summer. Laboratory Classes (LC)

FESASS General Assembly, 22 September 2011, Brussels. Financial aspects of infectious animal disease control and eradication

Planning Spring/Summer 2018

March 2017 Animal Care Conference, Sacramento, CA

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

A collaborative effortan investigation of suspect canine brucellosis

Components of Modified Kramer System

ANNEX. to the. Commission Implementing Decision

Procedures for the Taking of Prevention and Eradication Measures of Brucellosis in Bovine Animals

The Use of Homologous Antigen in the Serological Diagnosis of Brucellosis Caused by Brucella melitensis

Bovine Brucellosis Control of indirect ELISA kits

MANAGEMENT OF HUMAN EXPOSURES TO SUSPECT RABID ANIMALS A GUIDE FOR PHYSICIANS AND OTHER HEALTH CARE PROVIDERS. July 2010 Update

Selecting Foundation and Replacement Goats

Case Study Brucellosis: 2001 & Case Study Brucellosis: 2001 & Case Study Brucellosis: 2001 & Case Study Brucellosis: 2001 & 2002

They're not all the same: Why FDA approval of animal drugs matters

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Sustainable Worm Control Strategies for Sheep. LSSC Ltd

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

VETERINARY CERTIFICATE FOR IMPORT OF GOATS INTO INDIA

ANNEX Part 1 Model animal health certificate for imports into the Union of dogs, cats and ferrets COUNTRY:

Telephone Fax Mobile

TEXTS ADOPTED Provisional edition. P8_TA-PROV(2018)0429 Animal welfare, antimicrobial use and the environmental impact of industrial broiler farming

Transcription:

UNCLASSIFIED AD NUMBER AD815200 NEW LIMITATION CHANGE TO Approved for public release, distribution unlimited FROM Distribution authorized to U.S. Gov't. agencies and their contractors; Critical Technology; APR 1966. Other requests shall be referred to Army Biological LaboratoriesFort Detrick, Frederick, MD. AUTHORITY SMUFD D/A ltr, 14 Feb 1972 THIS PAGE IS UNCLASSIFIED

PI'11K,ESLTS OF STUDYING T1E1 4RUCELLA VACCINE FROM 111E RR. ABORTUS 104-M STRAIN Q Translation No /675 0 April 1966 STATEMENT #2 UNCLASSIFIED This doaument is subject to special export controls and each transmittcl to fori,-n governments or foreign nationals may be mane cnl, wl-i nricr -p *-o-al of U. SA AR --- BIOLOGICAL LABORATORIES FORT DETRICK, FREDERICK, MARYLAND

* ISCLAIMEI NOTICE THIS DOCUMENT IS BEST QUALITY AVAILABLE. THE COPY FURNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH DO NOT REPRODUCE LEGIBLY.

THE RESULTS OF STUDYINC THE BRUCELLA VACCINE FROM THE BR. ABORTUS 104-M STRAIN [Following is the translation of an article by I. F. Taran, Ye. I. Zamakhayeva, S. V. Abakin, A. M. Polyakova and N. M. Nelyapin, Kavkaz and Zakavkaz Scientific-Research Antiplague institute, published in the Russian-language periodical Zlurnai Mikrobiologii. Ppidemiologii i Immunobiologii (Journal of Microbiology, Epidemiology and Immunobiology) Vol 42, No 8, 1965, pages 99--104. It was submitted on I Jul 1964. Translation performed by Sp/7 Charles T. Ostertag, Jr.] In the Soviet Union the specific prophylaxis of brucellosis infection has occupied one of the leading places in the complex of antibrucellosis measures. In the last two decades extensive work has been carried out for the purpose of obtaining highly immunogenic strains for vaccination. As a result, foreign and Soviet scientists have proposed a number of vaccine strains, however the majority of them have not found subsequent application. The dr. abortus 19 vaccine strain has received international recognition. The relative intensity of immunity, created by this vaccine, caused the necessity for further searches. As a result of the work which was carried out in the laboratory of P. F. Zdrodovskiy, Kotlyarova (1950) proposed Br. abortus 104-M as a vaccine strain. It was distinguished by a somewhat greater residual virulence and a greater immunogenicity than the vaccine from the Br. abortus 19 strain. This was our basis for carrying out the present investigation. The work was made up of three sections: 1) a study of the harmlessness, immunological effectiveness and intensity of immunity, created by the Br. abortus 104-M vaccine in tests on guinea pf,,s; 2) a study of its harmlessness, immunological and epizootologicai effectiveness in tests on sheep; 3) a study of immunological and epidemiological effectiveness of the vaccine on humans. The investigations showed that following the administration of 10 and 100 microbial cells to guinea pigs, the insemination of the internal organs of animals which received Br. abortus 19 was 4 time less intense, and those which received Br. abortus 104-M -- 2 times less intense than following the administration of a virulent culture. The 104-M vaccine culture took root in the organism of man better than the culture of 19 fol+ lowing administration in doses of from 100 up to 1 million microbial cells. The intensity of immunity was more expressed in guinea pigs inoculated with the 104-M vaccine (table 1). 1.!I

In the group of guinea pigs which were inoculated with the 104-H vaccine, specific morphological changes developed following the administration of 10 million microbial cells and were characterized by a proliferative inflmanation in the form of hyperplasia of the reticular cells and the Kupffer cells in the liver, and the formation of granulomas out of the epithelioid cells in isolated lymph nodes and the spleen. In animals which were vaccinated with strain 19, all these symptoms were more weakly expressed, even following the administration of 100 million and 1 billion microbial cells. In the tests for studying the vaccine from the 104-M strain during cutaneous application, it was established that the minimum dose which conditioned P "eneralized infection equaled 1 million microbial cells. However, a wl.t expressed immunological reaction after a month following inoculation was caused by doses of no less than 100 million brucella. As a result of the morphological investigations it was established that the mechanism of development of the vaccine process during cutaneous application was analogous to its development during subcutaneous administration. Immunity in guinea pigs which were inoculated with 1 billion and 5 billion microbial cells developed in the period from the 3rd through the 9th months. By 12 months the intensity of immunity was noticeably lowered, and this lowering was more expressed in pigs which were inoculated with 5 billion microbial cells. The immunity which emerged following administration of vaccine from the 104-H strain developed slowly, and nonsusceptibility to infection with a virulent culture was achieved at the price of significant qualitative cianges in the lymph nodes and internal organs. Even in optimum periods (6 months) the intensity of immunity remained relative and bore a barrier nature. Thus, although strain 104-M was more immunogenic than strain 19, for the successful struggle with brucellosis in foci one specific prophylaxis is insufficient, and it is necessary that the entire complex of antibrucellosis measure be carried out along with it. Taking into consideration the considerable reactogenicity of vaccine from the 104-M strain, we undertook the mission of studying the bacteriology and morphological picture of the vaccinal process and also the intensity of immunity under the conditions of numerous revaccinations. As a result, it was established that in guinea pigs after a month following vaccination with 5 billion microbial cells a generalized process was noted with the abundant seeding of brucella from the lymph nodes and internal organs with an average titer of agglutinins up to 1:160 and an index of enlargement of the spleen up to 2 (in healthy guinea pigs from the same batch the index fluctuated from 0.8 up to 1.2). Following the first cutaneous revaccination with 2.5 billion microbial cells a generalization of the vaccine process was not observed. An insignificant increase in the titers of agglutinins and an increase of the spleen index up to 2.2 were noted. With the subsequent second and third revaccination there were 2.

moro guinea pigs with a generalized process than following the first vaccination. There was a lowering in the titers of agglutinins and the enlargement index of the spleen (1.3). In the lymph nodes and internal organs of the guinea pigs following repeated revaccination there were intensive changes in the form of necroses and abscisses, intensive eosinophilia in the lymph nodes and spleen, growth of scar tissue, atrophy of the Halpighian bodies of the spleen and necrobiosis of the hepatic cells, especially expressed following triple revacciration. Thus, it was established in the experimentalsection of our investigations that the 104-M vaccine was more reactogenic and immunogenic than the generally recognized 19 vaccine. The first one is capable of causing significant morphological shifts, which also guarantees its immuwagenicity. The main conclusions, characterizing the 104-M vaccine in the tests on guinea pigs, served as the basis for testing this vaccine on sheep. We used 185 healthy sheep for a comparative study of the two vaccine strains. As a result it was established that strain 104-M possessed more expressed immunogenic properties than the vaccine from strain 19. Thus, out of 23 sheep inoculated with the first preparation in a dose equal to 10 billion microbial cells, immunity developed in 22. In one animal there was a regional infection following infection after 11 months following vaccination. Out of 29 sheep inoculated with the second vaccine in the same dose and in the same periods, only.]b turned out to be immune. Six animals developed a regional infection and 5 animals a generalized infection. The study of the harmlessness of vaccine from strain 104-M was carried out on 56 pregnant sheep in the 2nd--3rd month of pregnancy. The sheep were vaccinated subcutaneously with 8 billion microbial cells based on the optical standard. Lambing on the part of the vaccinated animals proceeded normally, there were no abortions, and 63 healthy lambs were born. There was no less interest in studying immunity in sheep which were inoculated with 10 billion microbial cells with a subsequent revaccination. As a result, after 11 months following the first revaccination with strain IM4-M immunity was obtained against 50 generalized doses of a virulent strain in 60% of the test animals. Following revaccination with strain 19 such an immunity was obtained in only 20% of the sheep. After Il months following the second revaccination complete immunity had developed in 40 and 20% of the sheep respectively. The 104-M vaccine strain was stable and preserved its properties with great persistence. This is testified to by the tests on sheep and guinea pigs which were conducted in our laboratories for the last 6 years. All of these observations served as the basis for studying the new vaccine strain in an industrial experiment. Beginning with 1956 we, state and collective farms, jointly with the veterinarians from the inoculated 335,437 sheep with vaccine from 3.

strain 104-M. They came from unsafe flocks, where prior to the vaccination up to 257 of the sheep had brucellosis. The animals were vaccinated subcutaneously with 8--0 billion microbial cells. The sheep were vaccinated once with a subsequent second and third revaccination. Toe complex examination of the inoculated sheep was carried out in various periods following the vaccination end revaccination. The sheep were revaccinated after 10--l1 months and se.veral flocks of ewes were left without vaccination for 2--3 years. As a result of vaccination with strain 104-M abortions of a brucellosis etiology in sheep on brucellosis affected farms ceased, and there was an increase in the output of livestock from 89 up to 100-110 lambs per 100 eves. It should be noted that in individual years on the farms a significant drop-out of ewes and lambs was observed, and also extensive sterility by unsatisfactory feeding, ond the presence of other diseases among the animals. Along with this the epizootological nature of the farms in respect to brucellosis turned out satisfactori!7. In the aborted fetuses in several flocks, brucellosis cultures of the melitensis type were isolated only in the first 2 years following the onset of vaccination. Consequently brucellosis infection among immunized sheep was cut. Following the immunization of the animals with the 104-M vaccine the farms were economically stronger, they accomplished their production plans, and 110,960 healthy ewes were reared from female sheep which were derived from vaccinated sheep. During the study of the duration of immunity (table 2) it was established that immunological reaetigas in sheep which were vaccinated with strain 104-M were more expressed than in animals which were inocillated with strain 19, especially the allergic test. Together with this, by the end of the first year the postvaccinal reactions in animals of both groups has almost completely died away. After 2 years following ilnunization 25 sheep out of the group of anim;.ls which reacted positively were subjected to a bacteriological and biological investigation. No brucella cultures were isolated. Thus, the high immunogenicity of vaccine from strain 104-H creates a foundation for recommending it for the extensive vaccination of sheep. The experience of the mass vaccination of sheep with this vaccine on 8 farms in Stavropolskiy Kray confirmed its harmlessness and high epizootological effectiveness. At the same time we studied the feasibility of using the vaccine from Br. abortus strain 104-M for the specific prophylaxis of brucellosis infection in man. The study of the harmlessness and immunological effectiveness of the vaccine during subcutaneous and cutaneous application was carried out by means of vaccinating the adult population (from 17 to 55 years old) in brucellosis foci. All told 4392 persons were under observation. Of these, 612 were inoculated subcutaneoukly and 3730 cutaneously. 4.

t The following doses were used for subcutaneous inoculation: 100 million (545 men), 250 million and 300 million (all told 67 men) microbial cells. The larger doses were used for vaccination in the most active foc! of brucellosis, where infection of the professional group of the population reached 29%. In these groups people with negative immunological reactions for brucellosis were inoculated. It was established that during subcutaneous administration to man the vaccine from strain 104-H in quantities of 100 million microbial cells was harmless, caused an immunological reconstruction in the organism, and turned out to be completely acceptable based on reactogenicity. This supported the data which was obtained earlier by other investigators (Kotlyarova et al., 1959). In foci of brucellosis the subcutaneous administration of large doses oi vaccine (250--300 million microbial cells) cause.1 a significant general and local reaction, proceeding like a type of allergy, in 54% of those inoculated. This prevented the recommendation of the stated doses for the vaccination of man, though they did not lead to brucellosis infection. When studying the harmlessness and immunological effectiveness of vaccine from strain 104-M during cutaneous application, it was administered in the following doses: 1.5 billion, 3 billion, 5 billion, 7 billion, and 10 billion microbial cells. It was established that after 1--2k months following inoculation among those who were inoculated with 1.5 billion microbial cells 64% reacted weakly and positively, among those inoculated with 3 billion -- 79% among those inoculated with 5 billion -- 80-90%, and among those inoculated with 7--10 billion -- 73%. The degree of expression of the postvaccinal reactions depended on the professional composition of those inoculated. Thus, in groups of farmers the reactions were more expressed than in students. This may be explained by the presence among the inoculated farmers of persons who were sensitized to brucellosis infection and who were not detected during a single preliminary check. During the comparative study of the immunological effectiveness uf the vaccines when administered cutaneously in a dose of 5 billion microbial cells, it was established that strain 104-M is more immunogenic than strain 19. Thus, the test of cutaneous vaccination of persons with vaccine from strain 104-H showed its acceptable reactogenicity, harmlessness, and inmnunological effectiveness in doses of 100 million microbial cells during subcutaneous and 5 billion microbial cells during cutaneous application. The epidemiological effectiveness of the cutaneous method of immunization of persons with the 104-M vaccine was checked in 1959--1960 in 4 rayons cf Stavropolskiy Kray in the most active fresh foci of brucellosis among sheep and goats. Brucellosis was recorded in 40 out of the 56 sheep farms which were located in the rayons. Infection of animals reached 40-- 907 and mass abortions in sheep were noted. The brucellosis etiology of these abortions was confirmed bacteriologically. All told 51,446 men were 5.

inoculated. A vaccine was used which was prepared by the Scientific-Research Antiplague Institute for Kavkaz and Zakavkaz. One human dose comprised 3-5 billion microbial cells based on the optical standard. The inoculations were carried out from August through March, which was specified as the extended period for insemination and lambing for sheep according to economic plans. The effectiveness of the inoculations was taken into consideration over a period of 15 months following the immunization. Among 88 persons who became sick, 44 men were inoculated by the cutaneous method against brucellosis with vaccine from strain 104-M, 4 men -- with vaccine from strain 19, and the remaining 40 men turned out to be unvaccinated. Of the 44 men in the group inoculated with the 104-M vaccine who became sick, 11 had been inoculated more than once in the past with vaccine from strain 19. In all those who became sick the diagnosis was confirmed clinically and by immunological reactions, and in 27 men -- bacteriologically. In all cases the brucellosis causative agent of the goat-sheep type was isolated. Based on severity the clinical course of brucellosis in those who had been inoculated and those who had not was different. The disease in those who had been inoculated set in after 15 (1 man), 30 (3 men), 60 (4 men), 90 (7 men), 120-150 (16 men), 180--216 (10 men), and 240 ( 3 men) days. When calculating the effectiveness of inoculations by regions regardless of profession when comparing morbidity among non-inoculated and inoculated persons in the optimum periods (2--3 months prior to the beginning of lambing) the index of effectiveness turned out to be equal to 4, that is, there was 4 times less sickness among those inoculated than among the noninoculated. When calculating the effectiveness of inoculations individually by foci the disease was noted in 3.3% of those vaccinated in the optimum periods, and in 6.7% of those not inoculated. The index of effectiveness equaled 2. This very clearly showed the dependency of the effectiveness of inoculations on the epizootological situation on the farms. Thus, the experience of working in the foci showed that in the struggle with brucellosis foremost importance belongs to the specific prophylaxis of this disease in animals against a background of a rise in the public and sanitary culture on the farms. For this purpose vaccine from Br. abortus strain 104-M may be used with the greatest effectiveness. The presence of still another vaccine strain, which based on the main properties does not yield to the Br. abortus 19 strain, makes it possible to steadily equip the antiepidemic and antiepizootic service with a full-value vaccine. Conclusions 1. An experimental study of the vaccine strain of Br. abortus 104-M on guinea pigs supported its fine immunogenic properties during subcutaneous and cutaneous application, its ability to "take" and the ability to cause an 6.

active immunological reorganization. 2. During experimental testing on sheep, vaccine from the Br. abortus strain 1044M turned out to be harmless in doses of 8--10 billion microbial cells, it survived for a sufficiently long time in the organism, and it created an immurity which was more intense than that of Br. abortus 19. On the farms where the sheep were treated with the vaccine from this strain a sharp reduction was noted in the number of abortions, there was an increase in the output of healthy young stock, and a significant lowering of morbidity with brucellosis among the persons who take care of these animals. 3. Strain Br. abortus 104-M may be recommnended for the prophylactic vaccination of sheep for the purpose of forming healthy livestock. Literature 1. Kotlyarova, Kh. S., Zh. mikrobiology, 1950, No 6, page 13. 2. Kotlyarova, Kh. S., Polyakova, A. M., Lukashova, L. V., Vestn. AMN, USSR, 1959, No 2, page 42. 7

Table 1 Intensity of immunity in guinea pigs, infected with Br. melitensis 548 after 3 months following vaccination with Br. abortus Dose of vaccine (in 19 104-M microbia2 colls) Infected o ~4-I 0 t o.. C) T$ OC0 ;1.0 ~ 0 0 J0 00 ~.0 0 0 100 12 0 1 11 10 1 3 6 1000 12 2 2 8 12 4 2 6 10 000 12 1 3 8 12 5 6 1 100 000 11 4 2 5 11 7 4 0 1 000 000 11 2 4 5 12 10 2 0 10 000 000 12 2 4 6 11 7 3 1 100 000 000 12 4 6 2 12 6 5 1 1 000 000 000 12 8 2 2 12 10 2 0 Total.4 23 24 27 92 50 2V 15 8.

H~ coo00 000 o0 10 S.~ 0D CC)0 CY) L) ~CY 00Cr.I 000 to 0 *~o c*'* 0 ) ca 0 C) 0 C) OD N CY 0)0 ot C\3 0 ~ ( O00-1 010 4o Cý 0 tood in t 0- *.*.coo 0 0 LoCo- 00 CO 10-4 4 U ) 0) C0 C 0 g 0 Co o 000 0LO00 0 Oco 0 0 0 01 0 43 0-41 0 V.